Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 19,046

Document Document Title
WO/2014/190250A1
Methods for ameliorating and/or treating the symptoms associated with dystrophic diseases such as Duchenne muscular dystrophy (DMD) in a subject comprising administering to a subject a pharmaceutical composition comprising a nitric oxide...  
WO/2014/188214A1
A topical pharmaceutical composition for use in alleviating or reversing a clinical symptom selected from rigidity, stiffness, loss of mobility, loss of flexibility and swelling in a part or region of the body is described, wherein the c...  
WO/2014/188730A1
Provided is an agent for oral ingestion whereby human motility function can be improved. A motility function-improving agent that comprises lutein and a milk component as active ingredients, said motility function-improving agent being u...  
WO/2014/189475A1
The invention relates to a composition formed for treating the muscle weakness and the loss of muscle mass following the chronic stroke and coma.  
WO/2014/189071A1
 Provided are stem cells for transplantation composed of MSCs capable of overexpression of IL-10 as means for providing: MSCs for transplantation having improved take ratio and cell survivability after transplantation, and having high ...  
WO/2014/189830A1
Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formul...  
WO/2014/183989A1
The present invention relates to collagen hydrolysate as active substance for treating sarcopenia, as active substance against the degenerative loss of muscle mass and for improving muscle power, as active substance for reducing the age-...  
WO/2014/180996A1
The invention relates to the use of 5-azacytidine and pharmaceutically acceptable salts thereof in a method of treating or preventing diseases responsive to inhibition of nonsense-mediated mRNA decay, such as cystic fibrosis, muscular dy...  
WO/2014/181333A3
Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose. Also disclosed is an injectable aqueous pharmaceutical f...  
WO/2014/181813A1
The purpose of the present invention is to provide: a compound having excellent PKC inhibitory activity and is useful as a prophylactic or therapeutic agent for immunologic diseases and inflammatory diseases, etc.; or a salt thereof. The...  
WO/2014/178863A1
The present provides methods for treating spinal muscular atrophy using a self- complementary recombinant adeno-associated virus (rAAV) viral particle comprising a transgene expressing SMN. In one aspect, the viral particles are administ...  
WO/2014/171532A1
[Problem] To provide an anti-human TWEAK antibody having superior activity as compared to conventional anti-human TWEAK antibodies, and a means for preventing or treating various diseases in which human TWEAK is involved in the pathogene...  
WO/2014/169126A1
Agents and methods for increasing dystrophin protein expression in muscle through blocking of specific microRNAs and microRNA binding sites on the dystrophin 3' untranslated region (miR-146a, miRNA-146b, miR-223, miR-320a, miR374a, and m...  
WO/2014/167440A1
The present invention relates to modified release pharmaceutical compositions of cyclobenzaprine or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising unit dosage form o...  
WO/2014/162925A1
The present invention provides a composition for preventing joint aging, containing one or more types of components selected from the group consisting of a component containing rehmannia root, a component containing cornus fruit, a compo...  
WO/2014/165827A1
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demye...  
WO/2014/164969A1
The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.  
WO/2014/157437A1
A propellane derivative represented by general formula (I) (wherein R1 represents a hydrogen atom, a C1-6 alkyl group, a cycloalkylalkyl group (wherein the number of carbon atoms in a cycloalkyl moiety is 3 to 6 and the number of carbon ...  
WO/2014/157380A1
Provided is a means whereby wounds or organ fibrosis can be easily treated within a short period of time. A therapeutic agent for wounds or fibrosis, said therapeutic agent comprising a substance capable of specifically inhibiting the ex...  
WO/2014/157436A1
[Problem] The purpose of the present invention is to provide a formulation technique for improving the percutaneous absorption of diclofenac and/or a pharmaceutically acceptable salt thereof with respect to a pharmaceutical composition f...  
WO/2014/157153A1
A muscle-atrophy-preventing agent containing as active ingredients a milk-derived basic protein fraction and/or a milk-derived basic protein fraction decomposition product. The muscle-atrophy-preventing agent has marked effects for preve...  
WO/2014/160102A1
The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorde...  
WO/2014/153220A3
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.  
WO/2014/148455A1
Provided is a novel terpenoid derivative which exhibits anti-inflammatory action and cytoprotective action by activating Keap1/Nrf2/ARE signal transduction pathways. Terpenoid derivative A is represented by formula (1).  
WO/2014/148646A1
The present invention addresses the problems of: providing a method for producing motor neurons from pluripotent stem cells quickly and in synchronisation, said motor neurons being satisfactorily provided with the properties of inherent ...  
WO/2014/153240A3
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.  
WO/2014/153172A1
Described herein are compounds of Formula (I-a) and (I-b), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT1 activity. Methods of using ...  
WO/2014/148574A1
The purpose of the present invention is to find a substance capable of inhibiting the production of IL-2. The production of IL-2 can be inhibited with a compound represented by general formula (I) (wherein R1 to R4 and A are as defined i...  
WO/2014/144017A3
The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).  
WO/2014/139318A1
An application of a phthalide compound in preparing a medicament. The medicament is specially used for promoting a stem cell to secrete one of the following items: telomerase, a neurotrophic factor (brain-derived neurotrophic factor, BDN...  
WO/2014/144978A2
Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.  
WO/2014/142276A1
The objective of the present invention is to provide a compound having a superior neurotrophic factor-like effect. The present invention provides a medicine containing the compound as the active ingredient. The present invention pertains...  
WO/2014/144978A3
Improved compositions and methods for treating muscular dystrophy by administering eteplirsen, an antisense molecule capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, are described.  
WO/2014/145156A3
The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.  
WO/2014/145050A1
The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions...  
WO/2014/144978A8
Improved compositions and methods for treating muscular dystrophy by administering an antisense molecule such as eteplirsen, capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, are described.  
WO/2014/134225A3
Nutritive polypeptides are provided herein. Also provided are various other embodiments including pharmaceutical formulations containing the nutritive polypeptides, nucleic acids encoding the polypeptides, recombinant microorganisms that...  
WO/2014/127475A9
A composition for the treatment of perianal disorders. In particular, the composition includes three components: a) an analgesic, b) a cryoprotective agent and c) a muscle relaxant.  
WO/2014/127475A1
A composition for the treatment of perianal disorders. In particular, the composition includes three components: a) an analgesic, b) a cryoprotective agent and c) a muscle relaxant.  
WO/2014/123186A1
The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema3A protein participates, such as a neurode...  
WO/2014/122604A1
Disclosed is an extract of Polygonum fagopyrum for use in the prevention or treatment of a condition, disorder or disease involving a reduction in the endogenous testosterone level in males.  
WO/2014/118527A1
The present invention provides a topical composition comprising dantrolene and/or azumolene and one or more of a magnesium releasing compound and a compound which reacts with calcium ions under temperatures of 30 to 40 °C and pH levels ...  
WO/2014/120654A1
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2014/119753A4
[Problem] To provide a therapeutic drug that exhibits a strong, selective inhibitory activity against myostatin, and enables muscle hyperplasia and an increase in muscle mass. [Solution] A peptide selected from (a)-(d), below, or a pharm...  
WO/2014/119634A1
The objective of the present invention is to develop and provide a novel muscle-building agent in which a muscle hypertrophy promoter and a muscle atrophy therapeutic agent are active ingredients, which can induce muscle building without...  
WO/2014/119649A1
 The objective of the present invention is to provide a compound, or a salt thereof, having regulatory activity on the function of lysophosphatidylserine receptors. The present invention provides a compound, or a salt thereof, having...  
WO/2014/119753A1
[Problem] To provide a therapeutic drug that exhibits a strong, selective inhibitory activity against myostatin, and enables muscle hyperplasia and an increase in muscle mass. [Solution] A peptide selected from (a)-(d), below, or a pharm...  
WO/2014/113878A1
A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic age...  
WO/2014/113875A1
The present invention provides a method for the stimulation of secretion or expression of muscular IL-6 in a subject with the administration of Protectin DX (PDX). Particularly, the increase in circulating levels of IL-6 originating from...  
WO/2014/113932A1
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I) or pharmaceutically acceptable salts thereof. (Formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compo...  

Matches 201 - 250 out of 19,046